


## CLAIMS:

1. A cis-stilbene of formula



5

Wherein:

- 10 R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each independently alkyl,  
R<sup>4</sup> is alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl or halo,  
R<sup>5</sup> is hydrogen, alkoxy, alkyl, alkylthio, hydroxy or halo,  
or a pharmaceutically acceptable salt, solvate, hydrate or prodrug thereof.

- 15 2. A cis-stilbene according to claim 1 wherein  
R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are all methyl.

3. A cis-stilbene according to claim 2 wherein  
R<sup>5</sup> is hydrogen and R<sup>4</sup> is alkyl or halo.

20

4. (Z)-1-(3-hydroxy-4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene.

5. A prodrug of a cis-stilbene which is an carboxylic ester, phosphate ester,  
sulphate ester or carbonate of a cis-stilbene as claimed in any one of claims 1 to 3.

25

6. A prodrug of a cis-stilbene which is a phosphate ester of a cis-stilbene  
according to claim 1.

7. A prodrug according to claim 5 which is a dihydrogen phosphate ester.
8. (Z)-2-methyl-5-[2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl dihydrogen phosphate.
9. A composition for use in the treatment of neovascularisation which composition contains an effective amount of a cis-stilbene according to any one of claims 1 to 4 or a prodrug thereof according to any one of claims 5 to 8.
10. Use in the preparation of a composition for the treatment of neovascularisation of a cis-stilbene as claimed in any one of claims 1 to 4 or a prodrug thereof according to any one of claims 5 to 8.

5  
Sub  
A21

ADD A3